{
  "documentMetadata": {
    "title": "Endocarditis, Staph. aureus",
    "lastUpdated": "2025-05-06",
    "sourceFile": "Endocarditis, Staph. aureus.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Specific therapy for Staph. aureus endocarditis",
        "Signs and symptoms of endocarditis.",
        "Blood cultures positive for Staph. aureus. Susceptibility is known.",
        "For MRSA treatment failure see Staph. aureus Bacteremia."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Methicillin susceptible Staph. aureus (MSSA)",
        "Methicillin resistant Staph. aureus (MRSA)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "MSSA:"
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "condition": "Native valve",
            "components": [
              {
                "drug": "Nafcillin",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q4h"
              },
              {
                "drug": "Oxacillin",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q4h",
                "connector": "or"
              }
            ],
            "durationDetail": {
              "fixedDuration": "6 weeks"
            }
          }
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "condition": "Tricupsid valve, uncomplicated",
            "components": [
              {
                "drug": "Nafcillin",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q4h"
              },
              {
                "drug": "Oxacillin",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q4h",
                "connector": "or"
              }
            ],
            "durationDetail": {
              "fixedDuration": "4 weeks"
            }
          }
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "condition": "Prosthetic valve",
            "components": [
              {
                "drug": "Nafcillin",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q4h"
              },
              {
                "drug": "Oxacillin",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q4h",
                "connector": "or"
              },
              {
                "drug": "Rifampin",
                "dose": "600-900 mg/day",
                "route": "po/IV",
                "frequency": "in 2-3 divided doses",
                "connector": "+"
              },
              {
                "drug": "Gentamicin",
                "dose": "1 mg/kg",
                "route": "IV",
                "frequency": "q8h",
                "connector": "+"
              }
            ],
            "durationDetail": {
              "fixedDuration": "≥ 6 weeks"
            },
            "notes": "(see Antimicrobial Stewardship)"
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "MRSA:"
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "condition": "Native valve",
            "components": [
              {
                "drug": "Vancomycin",
                "dose": "15-20 mg/kg",
                "route": "IV",
                "frequency": "q8-12h"
              }
            ],
            "durationDetail": {
              "fixedDuration": "6 weeks"
            },
            "notes": "to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator); alternative is trough of 15-20 µg/mL)"
          }
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "condition": "Prosthetic valve",
            "components": [
              {
                "drug": "Vancomycin",
                "dose": "15-20 mg/kg",
                "route": "IV",
                "frequency": "q8-12h"
              },
              {
                "drug": "Rifampin",
                "dose": "600-900 mg/day",
                "route": "po/IV",
                "frequency": "in 2-3 divided doses",
                "connector": "+"
              },
              {
                "drug": "Gentamicin",
                "dose": "1 mg/kg",
                "route": "IV",
                "frequency": "q8h",
                "connector": "+"
              }
            ],
            "durationDetail": {
              "fixedDuration": "≥ 6 weeks"
            },
            "notes": "to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator); alternative is trough of 15-20 µg/mL) (see Antimicrobial Stewardship)"
          }
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "MSSA:"
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Cefazolin",
                "dose": "2 gm",
                "route": "IV",
                "frequency": "q8h"
              }
            ],
            "durationDetail": {
              "fixedDuration": "6 weeks"
            }
          }
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Vancomycin",
                "dose": "15-20 mg/kg",
                "route": "IV",
                "frequency": "q8-12h"
              }
            ],
            "durationDetail": {
              "fixedDuration": "6 weeks"
            },
            "notes": "to achieve preferred target AUC24 400-600 µg/mL x hr (see vancomycin AUC dosing calculator); alternative is trough of 15-20 µg/mL) (only in setting of major penicillin and cephalosporin allergy)"
          }
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Daptomycin",
                "dose": "8-12 mg/kg",
                "frequency": "q24h"
              }
            ],
            "durationDetail": {
              "fixedDuration": "6 weeks"
            }
          }
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "MRSA:"
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "components": [
              {
                "drug": "Daptomycin",
                "dose": "8-12 mg/kg",
                "frequency": "q24h"
              }
            ],
            "durationDetail": {
              "fixedDuration": "6 weeks"
            }
          }
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Targeting Vancomycin AUC preferred over trough concentration (Am J Health Sys Pharm 2020, 77:835).",
        "Wait 3-5 days after starting vancomycin/gentamicin before starting rifampin, to decrease bacterial density and thus minimize risk of selecting for rifampin resistance."
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "First-line choices:",
        "Nafcillin (or other anti-staphylococcal penicillin) or Cefazolin for MSSA (comparable to anti-staphylcoccal penicillins, see Antimicrob Agents Chemother 55:5122, 2011, Clin Infect Dis 59:369, 2014, and J Antimicrob Chemother 70:1539, 2015)",
        "Vancomycin or Daptomycin for MRSA (JAMA 312:1330, 2014).",
        "Daptomycin FDA-approved for right-sided endocarditis and bacteremia; case series suggests that high-dose daptomycin 8-12 mg/kg q24h is safe and also efficacious for left-sided endocarditis (J Antimicrob Chemother 68:936, 2013 & J Antimicrob Chemother 68:2921, 2013; J Infect Chemother 19:698, 2013; Antimicrob Agents Chemother 57:6213, 2013).",
        "American Heart Association (AHA) recommendations: Circulation 132:1435, 2015.",
        "Low-dose Gentamicin (1 mg/kg q8h) even for only a few days is nephrotoxic: not recommended except in prosthetic valve infection (Clin Infect Dis 48:713, 2009).",
        "Case reports of successful use of Telavancin for MRSA endocarditis, including infections caused by Vancomycin and Daptomycin non-susceptible strains (J Antimicrob Chemother 65:1315, 2010; Antimicrob Agents Chemother 54:5376, 2010; J Antimicrob Chemother 66:2186, 2011).",
        "Reported use of Ceftaroline alone and in combination (mostly with Daptomycin) for MRSA blood stream infections including endocarditis (J Antimicrob Chemother 67: 1267, 2012; J Infect Chemother 19: 42, 2013; Antimicrob Agents Chemother 61: e02015, 2017; Open Forum Infect Dis 4: ofx084, May 2, 2017 (PMID 28702467)).",
        "Recent publication describing risk factors for Staph. aureus endocarditis, S. aureus as the most common cause, and its association with healthcare (Clin Infect Dis 54:1230, 2012)."
      ]
    }
  ]
}
